Skip to content
ATLAS PREP HQ
Healing

BPC-157 + TB-500

Combination of BPC-157 with a thymosin-beta-4-derived TB-500 preparation

Combination research pairing BPC-157 and TB-500 for tissue repair, wound healing, and musculoskeletal recovery.

Preclinical Evidence

Route

Subcutaneous research/community use.

Common format

10 mg + 10 mg

Research focus

musculoskeletal recovery

Evidence level

Preclinical Evidence

Typical cycle

4–8 weeks

Healing research motifHealing

BPC-157 + TB-500 in 30 seconds

Atlas Fast Read

What it is

Combination of BPC-157 with a thymosin-beta-4-derived TB-500 preparation

Why people care

Combination research pairing BPC-157 and TB-500 for tissue repair, wound healing, and musculoskeletal recovery.

Human evidence

Preclinical Evidence — The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

Biggest misconception

Key gaps include validated human dosing, pharmacokinetics, long-term safety, clinically meaningful efficacy, product standardization, and independent replication in well-controlled trials.

Bottom line

BPC-157 + TB-500 is scientifically interesting for musculoskeletal recovery, wound repair, but the current case is driven mainly by cell and animal data.

Overview

What is BPC-157 + TB-500?

BPC-157 + TB-500 is a two-peptide research blend combining BPC-157 with a thymosin-beta-4-derived TB-500 preparation. The combination is popular in recovery communities, but the blend itself has not been validated in controlled human trials.

A community/research blend rather than a single drug-development product. It combines two compounds that became popular in regenerative-medicine and sports-recovery circles because their proposed repair mechanisms are different.

Mechanism

How it works

Combines BPC-157's proposed cytoprotective/angiogenic signaling with thymosin-beta-4-related effects on actin dynamics, cell migration, angiogenesis, and wound repair. Synergy is biologically plausible but not established in controlled human studies.

Research areas

musculoskeletal recoverywound repairtendon/ligament modelsangiogenesis

Evidence

What does the evidence actually say?

Preclinical Evidence

The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

01

Preclinical Evidence

02

Limited Human Evidence

03

Strong Human Evidence

Human evidence

There are no controlled human trials establishing the BPC-157 + TB-500 blend for injury recovery or wound healing. Human evidence on the exact combination is essentially absent.

Preclinical evidence

Preclinical rationale combines separate animal/cellular findings for BPC-157 and thymosin-beta-4-related peptides. Direct studies of the exact blend are limited or absent.

Knowledge gaps

Key gaps include validated human dosing, pharmacokinetics, long-term safety, clinically meaningful efficacy, product standardization, and independent replication in well-controlled trials.

Protocol

Research protocol

DoseFrequencyTimingCycle

Dose

Community reference: 500–1,500 mcg total blend/day, roughly 250–750 mcg of each peptide.

Frequency

Once daily in the community blended protocol.

Timing

No validated time-of-day requirement.

Route

Subcutaneous research/community use.

Cycle length

4–8 weeks

Reconstitution

Community reference: 2 mL bacteriostatic water per 20 mg blend = 10 mg/mL total, 5 mg/mL of each component.

Storage

Community reference: lyophilized frozen; reconstituted 2–8 °C and use within 14 days.

Monitoring

No validated monitoring standard. Use objective injury/function measures plus CBC/CMP if supervised; monitor injection reactions and any unexplained swelling or systemic symptoms.

Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.

Safety

Safety, side effects, and precautions

Side effects

Controlled human safety data are limited. Possible issues include injection-site reactions, headache, nausea, dizziness, fatigue and hypersensitivity. Because several proposed mechanisms involve angiogenesis or tissue-growth signaling, long-term systemic effects are uncertain.

Contraindications

No validated human contraindication profile exists. Pregnancy/breastfeeding, active malignancy, unexplained masses, major bleeding disorders or serious systemic illness warrant avoidance outside formal research/medical oversight.

Interactions

Formal interaction studies are lacking. Use with anticoagulants/antiplatelet drugs, growth-factor therapies, immunomodulators or other experimental repair peptides creates unknown additive risks.

Stacks

Common stacks

No well-supported stack is highlighted for this peptide yet.

Questions

FAQ

References

Sources

Atlas

The Atlas verdict

BPC-157 + TB-500 is scientifically interesting for musculoskeletal recovery, wound repair, but the current case is driven mainly by cell and animal data. Atlas would treat claimed benefits as hypotheses—not established human outcomes—and would put human safety, product quality, and controlled trials ahead of protocol optimization.

More in Healing

Healing

Ara-290

Innate-repair-receptor peptide research centered on inflammation, tissue protection, and neuropathy.

Read guide

Healing

BPC-157

Synthetic peptide studied primarily for tissue repair, cytoprotection, and gastrointestinal healing pathways.

Read guide

Healing

Cartalax

Short peptide bioregulator studied for connective-tissue support and fibroblast-related activity.

Read guide